Category: Pharma, Life Sciences & Med Tech Players
-
Novo Nordisk settles U.S. semaglutide patent infringement dispute, but denied Indian interim injunction again
While Novo Nordisk has struck an agreement with U.S. telehealth platform Hims & Hers to sell Ozempic and Wegovy, the Delhi High Court has once again denied its request for an interim injunction against Dr. Reddy’s Laboratories to block its sales of semaglutide products after its patent expires in 10 days.
-
An interview with bioMérieux IP head Dr. James Robertson
James Robertson, the in vitro diagnostics company’s global head of IP, talked to ip fray about its activities in the Unified Patent Court and some of the successes and hurdles he has experienced since moving from pharma into diagnostics IP management.
-
Moderna, Genevant, Arbutus settle global mRNA patent infringement dispute
Moderna could have to pay up to $2.25 billion as part of the settlement agreement, but remains confident it will close 2026 with up to $5 billion in cash and cash equivalents as a result of the deal.
-
Novo Nordisk targets Canadian pharma giant Apotex in new oral semaglutide patent infringement suit
Novo Nordisk has sued Canada’s Apotex in the United States District Court for the District of New Jersey over the alleged infringement of six patents related to its oral weightloss drug Rybelsus.
-
New COVID-19 vaccine patent suit: BioNTech v. Moderna
BioNTech has sued Moderna in the United States District Court for the District of Delaware, alleging that the defendant’s most profitable vaccine mNexspike infringes on its key RNA technology.
-
Astellas settles parallel bladder treatment patent suits against India’s Lupin, Zydus: licensing deals worth combined $210 million
Japanese pharmaceutical giant Astellas has signed patent licensing agreements with Indian rivals Lupin and Zydus worth over $210 million, ending all ongoing litigation between the companies in the District of Delaware.
-
Appeals court persuades Grünenthal to drop unfair competition law injunctions (obtained in parallel to patent PIs) against Abdi Farma
Grünenthal had won two different types of injunctions against Amdi Farma over painkillers: a patent PI (on appeal) and unfair competition PIs, which have just been lifted.
-
Novo Nordisk files fresh semaglutide patent infringement suit in District of Delaware
Novo Nordisk has sued telehealth medication provider Hims & Hers over the infringement of one of its semaglutide patents, as the company faces headwinds over its weightloss drugs for the first time in nearly a decade.
-
UPC’s Hague LD grants Abbott two preliminary injunctions, assumes long-arm jurisdiction (Spain) over German defendants, clarifies urgency requirement
The Unified Patent Court’s Hague LD has provided clarifications on long-arm jurisdiction and urgency that have applicabiliy beyond these two cases.
-
Cross-border injunctions “have their place” but can be “big ask”: Sandoz Global Head of IP Julia Pike
There is a place for cross-border injunctions, but in more nuanced cases (such as Regeneron v. Advanz) it’s a “big ask” for one country to take that decision itself on behalf of all those other countries, the company’s Global Head of IP Julia Pike has told ip fray.